•
Jun 30, 2020

Edgewise Therapeutics Q2 2020 Earnings Report

EPS
-$0.194
Research and development expenses
$3.6M
General and administrative expenses
$300K
Gross Profit
$0

Edgewise Therapeutics

Edgewise Therapeutics